The International Working Group (IWG) recommended that the diagnosis of AD should be based on both clinical and biomarker evidence,41 because a purely biological definition of AD, positive Aβ, and tau markers, do not always predict that dementia will occur in a patient's lifetime. This evidence concerns the gene MAPT and dementia.